Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer

BACKGROUND: Estrogen receptor (ER) positive breast cancer is often effectively treated with drugs that inhibit ER signaling, i.e., tamoxifen (TAM) and aromatase inhibitors (AIs). However, 30% of ER+ breast cancer patients develop resistance to therapy leading to tumour recurrence. Changes in the met...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Cancer
Main Authors: Soleimani Dodaran, Maryam, Borgoni, Simone, Sofyalı, Emre, Verschure, Pernette J., Wiemann, Stefan, Moerland, Perry D., van Kampen, Antoine H. C.
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2020
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7368985/
https://ncbi.nlm.nih.gov/pubmed/32684154
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-020-07100-z
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados